Helicobacter pylori vaccine - AstraZeneca/CSL

Drug Profile

Helicobacter pylori vaccine - AstraZeneca/CSL

Latest Information Update: 17 Oct 2001

Price : $50

At a glance

  • Originator CSL
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Helicobacter infections

Most Recent Events

  • 17 Oct 2001 Discontinued-Preclinical for Helicobacter infections in USA (PO)
  • 17 Oct 2001 Discontinued-Preclinical for Helicobacter infections in Australia (PO)
  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top